Pages Menu
FacebookTwitterPinterestRss
Categories Menu

Posted by on Oct 25, 2013 in Foundation NewsLine |

Update from Genzyme on Acid Sphingomyelinase Deficiency (ASMD) Development Efforts

Genzyme logo
Dear Friends and Families,

Genzyme, a Sanofi company, is pleased to update the Niemann-Pick disease patient community on the progress of efforts to develop a potential therapy for acid sphingomyelinase deficiency (ASMD, also known as Niemann-Pick disease Types A and B).